Club Warehouse Australia Pty Ltd - Результаты поиска

alphapharm pty ltd - flecainide acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate - supraventricular arrhythmias, due to pre-excitation syndromes (e.g wolff-parkinson-white and lown-ganong-levine syndromes) or to dual atrioventricular nodal pathways in patients with disabling symptoms; paroxysmal atrial flutter/fibrillation (paf) associated with disabling symptoms. although flecainide acetate may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecatab should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate. use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended. life-threatening ventricular arrhythmias not controlled by other drugs. an intravenous form of flecainide acetate is indicated when rapid control or short-term prophylaxis of the above arrhythmias is the main clinical requirement. all use of the injection (available in other brands) should be in hospitals only. flecatab is used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means. see warnings and precautions.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

flecatab flecainide acetate 50 mg tablet blister pack

alphapharm pty ltd - flecainide acetate, quantity: 50 mg - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium - flecainide is indicated for 1. supraventricular arrhythmias, ? due to pre-excitation syndromes (e.g. wolff-parkinson-white and lown-ganong-levine syndromes) ? due to dual atrioventricular (av) nodal pathways in patients with debilitating symptoms ? paroxysmal atrial flutter/fibrillation (paf) associated with disabling symptoms,although flecainide acetate may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecatab should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life-threatening ventricular arrhythmias not controlled by other drugs. an intravenous form of flecainide acetate is indicated when rapid control or short-term prophylaxis of the above arrhythmias is the main clinical requirement. all use of the injection (available in other brands) should be in hospitals only.,flecatab is used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult section 4.4 special warnings and precautions for use of this product information.

Австралия - английский - APVMA (Australian Pesticides and Veterinary Medicines Authority)

lasso herbicide by monsanto